Alterity Therapeutics Limited - ROE
PRNAF
Price:
$0.35
Market Cap:
$112.02M
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compo...[Read more]
Industry
Medical - Pharmaceuticals
IPO Date
2012-09-25
Stock Exchange
OTC
Ticker
PRNAF
PE Ratio
[-312.50]
ROE
[-30.19%]
Current Ratio
[21.98]
Dividend Yield
[0%]
Enterprise Value
[62.98M]
Dividend History
The ROE as of August 2026 (TTM) for Alterity Therapeutics Limited (PRNAF) is -30.19%
According to Alterity Therapeutics Limited’s latest financial reports and current stock price. The company's current ROE is -30.19%. This represents a change of -43.32% compared to the average of -53.25% of the last 4 quarters.
Alterity Therapeutics Limited (PRNAF) Historical ROE (quarterly & annually)
How has PRNAF ROE performed in the past?
The mean historical ROE of Alterity Therapeutics Limited over the last ten years is -58.97%. The current -30.19% ROE has changed -48.82% with respect to the historical average. Over the past ten years (40 quarters), PRNAF's ROE was at its highest in in the December 2014 quarter at -3.43%. The ROE was at its lowest in in the December 2010 quarter at -126.15%.
Average
-58.97%
Median
-50.82%
Minimum
-138.60%
Maximum
-24.64%
Alterity Therapeutics Limited (PRNAF) ROE by Quarter and Year
Discovering the peaks and valleys of Alterity Therapeutics Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 129.01%
Maximum Annual ROE = -24.64%
Minimum Annual Increase = -79.33%
Minimum Annual ROE = -138.60%
| Year | ROE | Change |
|---|---|---|
| 2025 | -28.65% | -79.33% |
| 2024 | -138.60% | 129.01% |
| 2023 | -60.52% | 67.09% |
| 2022 | -36.22% | -27.91% |
| 2021 | -50.24% | -47.32% |
| 2020 | -95.37% | 31.99% |
| 2019 | -72.26% | 40.58% |
| 2018 | -51.40% | 61.45% |
| 2017 | -31.84% | 29.20% |
| 2016 | -24.64% | 63.78% |
Alterity Therapeutics Limited (PRNAF) Average ROE
How has PRNAF ROE performed in the past?
The current ROE of Alterity Therapeutics Limited (PRNAF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-75.92%
5-year avg
-62.85%
10-year avg
-58.97%
Alterity Therapeutics Limited (PRNAF) ROE vs. Peers
How is PRNAF’s ROE compared to its peers?
Alterity Therapeutics Limited’s ROE is greater than BioStem Technologies, Inc. (-47.03%), greater than Nicox S.A. (-51.16%), greater than IXICO plc (-16.18%), greater than Clara Technologies Corp. (-84.68%), greater than Imugene Limited (-134.65%), greater than Actinogen Medical Limited (-134.14%), greater than Starpharma Holdings Limited (-15.96%), greater than Helix BioPharma Corp. (-21.54%), greater than PsyBio Therapeutics Corp (-867.29%), greater than Satellos Bioscience Inc. (-51.42%),
| Company | ROE | Market cap |
|---|---|---|
| -47.03% | $56.62M | |
| -51.16% | $29.17M | |
| -16.18% | $6.51M | |
| -84.68% | $3.60M | |
| -134.65% | $27.04M | |
| -134.14% | $2.97M | |
| -15.96% | $217.62M | |
| -21.54% | $130.61M | |
| -867.29% | $1.27K | |
| -51.42% | $96.62M |
Build a custom stock screener for Alterity Therapeutics Limited (PRNAF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alterity Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Alterity Therapeutics Limited (PRNAF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Alterity Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Alterity Therapeutics Limited's ROE?
How is the ROE calculated for Alterity Therapeutics Limited (PRNAF)?
What is the highest ROE for Alterity Therapeutics Limited (PRNAF)?
What is the 3-year average ROE for Alterity Therapeutics Limited (PRNAF)?
What is the 5-year average ROE for Alterity Therapeutics Limited (PRNAF)?
How does the current ROE for Alterity Therapeutics Limited (PRNAF) compare to its historical average?